Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2′,3′-Substituted Purine- and Pyrimidine Nucleotide Inhibitors

Tung-Chung Mou, Andreas Gille, Srividya Suryanarayana, Mark Richter, Roland Seifert and Stephen R. Sprang
Molecular Pharmacology September 2006, 70 (3) 878-886; DOI: https://doi.org/10.1124/mol.106.026427
Tung-Chung Mou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Gille
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srividya Suryanarayana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Richter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland Seifert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen R. Sprang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Membrane adenylyl cyclases (mACs) play an important role in signal transduction and are therefore potential drug targets. Earlier, we identified 2′,3′-O-(N-methylanthraniloyl) (MANT)-substituted purine nucleotides as a novel class of highly potent competitive mAC inhibitors (Ki values in the 10 nM range). MANT nucleotides discriminate among various mAC isoforms through differential interactions with a binding pocket localized at the interface between the C1 and C2 domains of mAC. In this study, we examine the structure/activity relationships for 2′,3′-substituted nucleotides and compare the crystal structures of mAC catalytic domains (VC1:IIC2) bound to MANT-GTP, MANT-ATP, and 2′,3′-(2,4,6-trinitrophenyl) (TNP)-ATP. TNP-substituted purine and pyrimidine nucleotides inhibited VC1:IIC2 with moderately high potency (Ki values in the 100 nM range). Elongation of the linker between the ribosyl group and the MANT group and substitution of N-adenine atoms with MANT reduces inhibitory potency. Crystal structures show that MANT-GTP, MANT-ATP, and TNP-ATP reside in the same binding pocket in the VC1:IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC. Fluorescence emission and resonance transfer spectra also reflect differences in the interaction between MANT-ATP and VC1:IIC2 relative to MANT-GTP. Our data are indicative of a three-site mAC pharmacophore; the 2′,3′-O-ribosyl substituent and the polyphosphate chain have the largest impact on inhibitor affinity and the nucleotide base has the least. The mAC binding site exhibits broad specificity, accommodating various bases and fluorescent groups at the 2′,3′-O-ribosyl position. These data should greatly facilitate the rational design of potent, isoform-selective mAC inhibitors.

Footnotes

  • This work was supported by National Institutes of Health grant DK46371 (to S.R.S.), Welch Foundation grant I-229 (to S.R.S.), the John W. and Rhoda K. Pate Professorship (to S.R.S.), grant 0450120Z from the Heartland Affiliate of the American Heart Association (to R.S.), the Graduate Training Program (Graduiertenkolleg) 760 “Medicinal Chemistry: Molecular Recognition-Ligand-Receptor Interactions” of the Deutsche Forschungsgemeinschaft (to R.S.), and a predoctoral fellowship from the Studienstiftung des Deutschen Volkes (to A.G.).

  • ABBREVIATIONS: AC, adenylyl cyclase; mAC, membrane-bound adenylyl cyclase; Gαs, stimulatory G-protein for mAC; FSK, forskolin; MP-FSK, 7-acetyl-7-[O-(N-methylpiperazino)-γ-butyryl)]-forskolin; VC1 and IIC2, the N- and C-terminal catalytic domains from canine type V mAC and rat type II mAC, respectively, expressed as soluble proteins; GTPγS, guanosine 5′-[γ-thio]triphosphate; SVD, singular value decomposition; FRET, fluorescence resonance energy transfer; MABA, 8-[(4-(N-methylanthraniloyl)amino)butyl]amino; MAHA, 8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino; MANT, 2′(3′)-O-(N-methylanthraniloyl); 6-MANT, N6-[6-((N-methylanthraniloyl)amino)hexyl]; MANT-EDA, 2,3,-[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]; TNP, 2′,3′-O-(2,4,6-trinitrophenyl).

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

  • ↵1 Current affiliation: Department of Pharmacology, University of Heidelberg, Heidelberg, Germany.

    • Received May 8, 2006.
    • Accepted June 8, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 70 (3)
Molecular Pharmacology
Vol. 70, Issue 3
1 Sep 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2′,3′-Substituted Purine- and Pyrimidine Nucleotide Inhibitors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2′,3′-Substituted Purine- and Pyrimidine Nucleotide Inhibitors

Tung-Chung Mou, Andreas Gille, Srividya Suryanarayana, Mark Richter, Roland Seifert and Stephen R. Sprang
Molecular Pharmacology September 1, 2006, 70 (3) 878-886; DOI: https://doi.org/10.1124/mol.106.026427

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2′,3′-Substituted Purine- and Pyrimidine Nucleotide Inhibitors

Tung-Chung Mou, Andreas Gille, Srividya Suryanarayana, Mark Richter, Roland Seifert and Stephen R. Sprang
Molecular Pharmacology September 1, 2006, 70 (3) 878-886; DOI: https://doi.org/10.1124/mol.106.026427
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Protocol-dependent differences in IC50 values measured in hERG assays occur in a predictable way and can be used to quantify state preference of drug binding.
  • Statins perturb Gβγ signaling and cell behaviors in a Gγ subtype dependent manner
  • A comparison of the ability of Leu8- and Pro8-oxytocin to regulate intracellular Ca2+ and Ca2+-activated K+ channels at human and marmoset oxytocin receptors.
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics